{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:01:18Z","timestamp":1784134878468,"version":"3.55.0"},"reference-count":45,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010418","name":"Institute for Information and Communications Technology Promotion","doi-asserted-by":"publisher","award":["2020-0-01108"],"award-info":[{"award-number":["2020-0-01108"]}],"id":[{"id":"10.13039\/501100010418","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Vonoprazan (VPZ) is the first-in-class potassium-competitive acid blocker (P-CAB), and has many advantages over proton pump inhibitors (PPIs). It is administered as a fumarate salt for the treatment of acid-related diseases, including reflux esophagitis, gastric ulcer, and duodenal ulcer, and for eradication of Helicobacter pylori. To discover novel cocrystals of VPZ, we adopted an artificial neural network (ANN)-based machine learning model as a virtual screening tool that can guide selection of the most promising coformers for VPZ cocrystals. Experimental screening by liquid-assisted grinding (LAG) confirmed that 8 of 19 coformers selected by the ANN model were likely to create new solid forms with VPZ. Structurally similar benzenediols and benzenetriols, i.e., catechol (CAT), resorcinol (RES), hydroquinone (HYQ), and pyrogallol (GAL), were used as coformers to obtain phase pure cocrystals with VPZ by reaction crystallization. We successfully prepared and characterized three novel cocrystals: VPZ\u2013RES, VPZ\u2013CAT, and VPZ\u2013GAL. VPZ\u2013RES had the highest solubility among the novel cocrystals studied here, and was even more soluble than the commercially available fumarate salt of VPZ in solution at pH 6.8. In addition, novel VPZ cocrystals had superior stability in aqueous media than VPZ fumarates, demonstrating their potential for improved pharmaceutical performance.<\/jats:p>","DOI":"10.3390\/pharmaceutics14020429","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T21:36:24Z","timestamp":1645047384000},"page":"429","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Novel Cocrystals of Vonoprazan: Machine Learning-Assisted Discovery"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5273-7408","authenticated-orcid":false,"given":"Min-Jeong","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Engineering, Soonchunhyang University, Asan 31538, Chungnam, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Yoon","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Medical Science, Soonchunhyang University, Asan 31538, Chungnam, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Medical Science, Soonchunhyang University, Asan 31538, Chungnam, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Seo","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Medical Science, Soonchunhyang University, Asan 31538, Chungnam, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6893-6281","authenticated-orcid":false,"given":"Medard E.","family":"Mswahili","sequence":"additional","affiliation":[{"name":"Department of ICT Convergence, Soonchunhyang University, Asan 31538, Chungnam, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9441-2940","authenticated-orcid":false,"given":"Young-Seob","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Computer Engineering, Chungbuk National University, Cheongju 28644, Chungbuk, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3038-4303","authenticated-orcid":false,"given":"Guang J.","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Engineering, Soonchunhyang University, Asan 31538, Chungnam, Korea"},{"name":"Department of Medical Science, Soonchunhyang University, Asan 31538, Chungnam, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pharmthera.2016.08.001","article-title":"Potassium-competitive Acid Blockers: Advanced Therapeutic Option for Acid-Related Diseases","volume":"168","author":"Inatomi","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1124\/jpet.110.170274","article-title":"1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases","volume":"335","author":"Hori","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5056\/jnm18139","article-title":"Role of Acid Suppression in Acid-Related Diseases: Proton Pump Inhibitor and Potassium-Competitive Acid Blocker","volume":"25","author":"Mori","year":"2019","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"754849","DOI":"10.3389\/fphar.2021.754849","article-title":"Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects","volume":"12","author":"Hwang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000475658","article-title":"Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease","volume":"95","author":"Okuyama","year":"2017","journal-title":"Digestion"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/apt.13325","article-title":"Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects\u2014A randomised open-label cross-over study","volume":"42","author":"Sakurai","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40265-015-0368-z","article-title":"Vonoprazan: First Global Approval","volume":"75","year":"2015","journal-title":"Drugs"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1136\/gutjnl-2017-314010","article-title":"Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: Randomised, lansoprazole-controlled non-inferiority and single-blind extension study","volume":"67","author":"Mizokami","year":"2018","journal-title":"Gut"},{"key":"ref_9","unstructured":"(2021, December 14). Phathom Pharmaceuticals. Available online: https:\/\/www.globenewswire.com\/news-release\/2021\/09\/08\/2293340\/0\/en\/Phathom-Pharmaceuticals-Submits-Two-NDAs-to-U-S-FDA-for-Vonoprazan-based-Treatment-Regimens-for-the-Treatment-of-H-pylori-Infection.html."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Karagianni, A., Malamatari, M., and Kachrimanis, K. (2018). Pharmaceutical cocrystals: New solid phase modification approaches for the formulation of APIs. Pharmaceutics, 10.","DOI":"10.3390\/pharmaceutics10010018"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1021\/acs.cgd.8b00933","article-title":"Creating cocrystals: A review of pharmaceutical cocrystal preparation routes and applications","volume":"18","author":"Padrela","year":"2018","journal-title":"Cryst. Growth Des."},{"key":"ref_12","first-page":"82","article-title":"Poor aqueous solubility\u2014An industry wide problem in drug discovery","volume":"5","author":"Lipinski","year":"2002","journal-title":"Am. Pharm. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"780582","DOI":"10.3389\/fphar.2021.780582","article-title":"Recent Advances in Pharmaceutical Cocrystals: From Bench to Market","volume":"12","author":"Rout","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1021\/acs.cgd.5b01605","article-title":"Olanzapine Salts and Diversity in Molecular Packing","volume":"16","author":"Sarmah","year":"2016","journal-title":"Cryst. Growth Des."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/acs.cgd.8b01451","article-title":"Salt\/Cocrystal of AntiFibrinolytic Hemostatic Drug Tranexamic Acid: Structural, DFT, and Stability Study of Salt\/Cocrystal with GRAS Molecules","volume":"19","author":"Nechipadappu","year":"2019","journal-title":"Cryst. Growth Des."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"121063","DOI":"10.1016\/j.ijpharm.2021.121063","article-title":"Cocrystals, Salts, and Salt-Solvates of olanzapine; selection of coformers and improved solubility","volume":"608","author":"Gong","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1021\/cg300002p","article-title":"High solubility piperazine salts of the nonsteroidal anti-inflammatory drug (NSAID) meclofenamic acid","volume":"12","author":"Sanphui","year":"2012","journal-title":"Cryst. Growth Des."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Guan, D., Xuan, B., Wang, C., Long, R., Jiang, Y., Mao, L., Kang, J., Wang, Z., Chow, S.F., and Zhou, Q. (2021). Improving the Physicochemical and Biopharmaceutical Properties of Active Pharmaceutical Ingredients Derived from Traditional Chinese Medicine through Cocrystal Engineering. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13122160"},{"key":"ref_19","unstructured":"Food and Drug Administration (2018). Regulatory Classification of Pharmaceutical Co-Crystals Guidance for Industry, Food and Drug Administration."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.1039\/D1CE00825K","article-title":"Cocrystal Engineering of Pharmaceutical Solids: Therapeutic Potentials and Challenges","volume":"23","author":"Wong","year":"2021","journal-title":"CrystEngComm"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.1039\/c4ce00316k","article-title":"Knowledge-based approaches to co-crystal design","volume":"16","author":"Wood","year":"2014","journal-title":"CrystEngComm"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Abramov, Y.A. (2016). Computational Pharmaceutical Solid State Chemistry, John Wiley & Sons, Inc.","DOI":"10.1002\/9781118700686"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/10610278.2019.1693043","article-title":"Evaluating hydrogen-bond propensity, hydrogen-bond coordination and hydrogen-bond energy as tools for predicting the outcome of attempted co-crystallisations","volume":"32","author":"Sarkar","year":"2020","journal-title":"Supramol. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1021\/cg401339v","article-title":"Validation of a Computational Cocrystal Prediction Tool: Comparison of Virtual and Experimental Cocrystal Screening Results","volume":"14","author":"Grecu","year":"2014","journal-title":"Cryst. Growth Des."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7618","DOI":"10.1021\/acs.cgd.8b01413","article-title":"Combined Virtual\/Experimental Multicomponent Solid Forms Screening of Sildenafil: New Salts, Cocrystals, and Hybrid Salt\u2013Cocrystals","volume":"18","author":"Barbas","year":"2018","journal-title":"Cryst. Growth Des."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ijpharm.2019.01.007","article-title":"Reliability of the Hansen solubility parameters as co-crystal formation prediction tool","volume":"558","author":"Salem","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1002\/jps.23227","article-title":"Rational Coformer or Solvent Selection for Pharmaceutical Cocrystallization or Desolvation","volume":"101","author":"Abramov","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"8832","DOI":"10.1021\/acs.jpclett.0c02371","article-title":"Virtual Coformer Screening by Crystal Structure Predictions: Crucial Role of Crystallinity in Pharmaceutical Cocrystallization","volume":"11","author":"Sun","year":"2020","journal-title":"J. Phys. Chem. Lett."},{"key":"ref_29","unstructured":"Chackalamannil, S., Rotella, D., and Ward, S.E. (2017). Empirical and Physics-Based Calculations of Physical\u2212Chemical Properties. Comprehensive Medicinal Chemistry III, Elsevier. [3rd ed.]."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1039\/C7CE00587C","article-title":"Will they co-crystallize?","volume":"19","author":"Wicker","year":"2017","journal-title":"CrystEngComm"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1021\/acs.cgd.9b00318","article-title":"Application of multivariate adaptive regression splines (MARSplines) Methodology for screening of dicarboxylic acid cocrystal using 1D and 2D molecular descriptors","volume":"19","author":"Cysewski","year":"2019","journal-title":"Cryst. Growth Des."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1021\/acs.cgd.0c00767","article-title":"Machine-learning-guided cocrystal prediction based on large data base","volume":"20","author":"Wang","year":"2020","journal-title":"Cryst. Growth Des."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1021\/acs.cgd.1c00211","article-title":"Cocrystals of Praziquantel: Discovery by Network-Based Link Prediction","volume":"21","author":"Devogelaer","year":"2021","journal-title":"Cryst. Growth Des."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Mswahili, M.E., Lee, M.-J., Martin, G.L., Kim, J., Kim, P., Choi, G.J., and Jeong, Y.-S. (2021). Cocrystal Prediction Using Machine Learning Models and Descriptors. Appl. Sci., 11.","DOI":"10.3390\/app11031323"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"8528","DOI":"10.1039\/C6CE01835A","article-title":"Co-crystallization and small molecule crystal form diversity: From pharmaceutical to materials applications","volume":"18","author":"Cherukuvada","year":"2016","journal-title":"CrystEngComm"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6991","DOI":"10.1039\/C9CE01160A","article-title":"Affinity prediction computations and mechanosynthesis of carbamazepine based cocrystals","volume":"21","author":"Correia","year":"2019","journal-title":"CrystEngComm"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1124\/jpet.111.179556","article-title":"A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals","volume":"337","author":"Hori","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1021\/mp0601345","article-title":"The Salt\u2212Cocrystal Continuum: The Influence of Crystal Structure on Ionization State","volume":"4","author":"Childs","year":"2007","journal-title":"Mol. Pharm."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5534","DOI":"10.1021\/acs.cgd.8b00849","article-title":"Cocrystallization of Curcumin with Benzenediols and Benzenetriols via Rapid Solvent Removal","volume":"18","author":"Wong","year":"2018","journal-title":"Cryst. Growth Des."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1039\/D0CE00106F","article-title":"Cocrystals\/salt of 1-naphthaleneacetic acid and utilizing Hirshfeld surface calculations for acid\u2013aminopyrimidine synthons","volume":"22","author":"Garg","year":"2020","journal-title":"CrystEngComm"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF01197379","article-title":"On the polymorphism of pharmaceuticals and other molecular crystals. I","volume":"72","author":"Burger","year":"1979","journal-title":"Microchim. Acta"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Mayo, D.W., Miller, F.A., and Hannah, R.W. (2003). Course Notes on the Interpretation of Infrared and Raman Spectra, John Wiley & Sons, Inc.","DOI":"10.1002\/0471690082"},{"key":"ref_43","unstructured":"Socrates, G. (2001). Infrared and Raman Characteristic Group Frequencies: Tables and Charts, John Wiley & Sons, Inc.. [3rd ed.]."},{"key":"ref_44","first-page":"12","article-title":"FTIR, FT Raman spectra and molecular structural confirmation of isoniazid","volume":"47","author":"Gunasekaran","year":"2009","journal-title":"Indian J. Pure Appl. Phys."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jchromb.2017.05.013","article-title":"Study on pharmacokinetics and bioequivalence of Vonoprazan pyroglutamate in rats by liquid chromatography with tandem mass spectrometry","volume":"1059","author":"Qiao","year":"2017","journal-title":"J. Chromatogr. B"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/2\/429\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:21:09Z","timestamp":1760134869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/2\/429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,16]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["pharmaceutics14020429"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14020429","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,16]]}}}